APO Research
Talk to an analyst

APO RESEARCH · REPORT

Obesity Diagnosis and Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Obesity Diagnosis and Treatment Market Outlook and Growth Opportunities 2026

3 May 2026192 pages

Choose your research edition.

Industry ResearchObesity Diagnosis and Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Obesity Diagnosis and Treatment Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Obesity Diagnosis and Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Obesity Diagnosis and Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Obesity Diagnosis and Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Obesity Diagnosis and Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Obesity Diagnosis and Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Obesity Diagnosis and Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Obesity Diagnosis and Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Obesity Diagnosis and Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Obesity Diagnosis and Treatment market include Obesity diagnosis and treatment, GlaxoSmithKline, Arena Pharmaceuticals, Pfizer, Allergan, Obalon Therapeutics, Nalpropion Pharmaceuticals, Novo Nordisk and Beijing Noble Laser Technology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Obesity Diagnosis and Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Obesity Diagnosis and Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Obesity Diagnosis and Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Obesity Diagnosis and Treatment market.

Obesity Diagnosis and Treatment Segment by Company

Obesity diagnosis and treatment

GlaxoSmithKline

Arena Pharmaceuticals

Pfizer

Allergan

Obalon Therapeutics

Nalpropion Pharmaceuticals

Novo Nordisk

Beijing Noble Laser Technology

Eisai

Orexigen Therapeutics

ReShape Lifesciences

Roche

Allurion Technologies

Medtronic

VIVUS

ApolloEndosurgery

Ethicon, Inc.

AstraZeneca

Takeda Pharmaceutical Company

Currax Pharmaceuticals

Obesity Diagnosis and Treatment Segment by Type

Medication

Surgery

Fitness

Others

Obesity Diagnosis and Treatment Segment by Application

<18 Years Old

18-35 Years Old

36-45 Years Old

45-55 Years Old

>55 Years Old

Obesity Diagnosis and Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Obesity Diagnosis and Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Obesity Diagnosis and Treatment key companies, revenue, market share, and recent developments.

3. To split the Obesity Diagnosis and Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Obesity Diagnosis and Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Obesity Diagnosis and Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Obesity Diagnosis and Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obesity Diagnosis and Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Obesity Diagnosis and Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obesity Diagnosis and Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Obesity Diagnosis and Treatment industry.

Chapter 3: Detailed analysis of Obesity Diagnosis and Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Obesity Diagnosis and Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Obesity Diagnosis and Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Obesity Diagnosis and Treatment Industry Trends Table 2. Obesity Diagnosis and Treatment Industry Drivers Table 3. Obesity Diagnosis and Treatment Industry Opportunities and Challenges Table 4. Obesity Diagnosis and Treatment Industry Restraints Table 5. Global Obesity Diagnosis and Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Obesity Diagnosis and Treatment Revenue Share by Company (2021-2026) Table 7. Global Obesity Diagnosis and Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Obesity Diagnosis and Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Obesity Diagnosis and Treatment Company, Product Type & Application Table 10. Global Obesity Diagnosis and Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Obesity Diagnosis and Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Medication Table 15. Significant Companies of Surgery Table 16. Significant Companies of Fitness Table 17. Significant Companies of Others Table 18. Global Obesity Diagnosis and Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Obesity Diagnosis and Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Obesity Diagnosis and Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Obesity Diagnosis and Treatment Sales Value Share by Type (2021-2026) Table 22. Global Obesity Diagnosis and Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of <18 Years Old Table 24. Significant Companies of 18-35 Years Old Table 25. Significant Companies of 36-45 Years Old Table 26. Significant Companies of 45-55 Years Old Table 27. Significant Companies of >55 Years Old Table 28. Global Obesity Diagnosis and Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Obesity Diagnosis and Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Obesity Diagnosis and Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Obesity Diagnosis and Treatment Sales Value Share by Application (2021-2026) Table 32. Global Obesity Diagnosis and Treatment Sales Value Share by Application (2027-2032) Table 33. Global Obesity Diagnosis and Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Obesity Diagnosis and Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Obesity Diagnosis and Treatment Sales Value Share by Region (2021-2026) Table 36. Global Obesity Diagnosis and Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Obesity Diagnosis and Treatment Sales Value Share by Region (2027-2032) Table 38. Global Obesity Diagnosis and Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Obesity Diagnosis and Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Obesity Diagnosis and Treatment Sales Value Market Share by Country (2021-2026) Table 41. Global Obesity Diagnosis and Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Obesity Diagnosis and Treatment Sales Value Market Share by Country (2027-2032) Table 43. Obesity diagnosis and treatment Company Information Table 44. Obesity diagnosis and treatment Business Overview Table 45. Obesity diagnosis and treatment Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Obesity diagnosis and treatment Obesity Diagnosis and Treatment Product Portfolio Table 47. Obesity diagnosis and treatment Recent Development Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline Obesity Diagnosis and Treatment Product Portfolio Table 52. GlaxoSmithKline Recent Development Table 53. Arena Pharmaceuticals Company Information Table 54. Arena Pharmaceuticals Business Overview Table 55. Arena Pharmaceuticals Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Arena Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio Table 57. Arena Pharmaceuticals Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Obesity Diagnosis and Treatment Product Portfolio Table 62. Pfizer Recent Development Table 63. Allergan Company Information Table 64. Allergan Business Overview Table 65. Allergan Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Allergan Obesity Diagnosis and Treatment Product Portfolio Table 67. Allergan Recent Development Table 68. Obalon Therapeutics Company Information Table 69. Obalon Therapeutics Business Overview Table 70. Obalon Therapeutics Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Obalon Therapeutics Obesity Diagnosis and Treatment Product Portfolio Table 72. Obalon Therapeutics Recent Development Table 73. Nalpropion Pharmaceuticals Company Information Table 74. Nalpropion Pharmaceuticals Business Overview Table 75. Nalpropion Pharmaceuticals Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nalpropion Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio Table 77. Nalpropion Pharmaceuticals Recent Development Table 78. Novo Nordisk Company Information Table 79. Novo Nordisk Business Overview Table 80. Novo Nordisk Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novo Nordisk Obesity Diagnosis and Treatment Product Portfolio Table 82. Novo Nordisk Recent Development Table 83. Beijing Noble Laser Technology Company Information Table 84. Beijing Noble Laser Technology Business Overview Table 85. Beijing Noble Laser Technology Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Beijing Noble Laser Technology Obesity Diagnosis and Treatment Product Portfolio Table 87. Beijing Noble Laser Technology Recent Development Table 88. Eisai Company Information Table 89. Eisai Business Overview Table 90. Eisai Obesity Diagnosis and Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Eisai Obesity Diagnosis and Treatment Product Portfolio Table 92. Eisai Recent Development Table 93. Orexigen Therapeutics Company Information Table 94. Orexigen Therapeutics Business Overview Table 95. Orexigen Therapeutics Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Orexigen Therapeutics Obesity Diagnosis and Treatment Product Portfolio Table 97. Orexigen Therapeutics Recent Development Table 98. ReShape Lifesciences Company Information Table 99. ReShape Lifesciences Business Overview Table 100. ReShape Lifesciences Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. ReShape Lifesciences Obesity Diagnosis and Treatment Product Portfolio Table 102. ReShape Lifesciences Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Roche Obesity Diagnosis and Treatment Product Portfolio Table 107. Roche Recent Development Table 108. Allurion Technologies Company Information Table 109. Allurion Technologies Business Overview Table 110. Allurion Technologies Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Allurion Technologies Obesity Diagnosis and Treatment Product Portfolio Table 112. Allurion Technologies Recent Development Table 113. Medtronic Company Information Table 114. Medtronic Business Overview Table 115. Medtronic Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Medtronic Obesity Diagnosis and Treatment Product Portfolio Table 117. Medtronic Recent Development Table 118. VIVUS Company Information Table 119. VIVUS Business Overview Table 120. VIVUS Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. VIVUS Obesity Diagnosis and Treatment Product Portfolio Table 122. VIVUS Recent Development Table 123. ApolloEndosurgery Company Information Table 124. ApolloEndosurgery Business Overview Table 125. ApolloEndosurgery Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. ApolloEndosurgery Obesity Diagnosis and Treatment Product Portfolio Table 127. ApolloEndosurgery Recent Development Table 128. Ethicon, Inc. Company Information Table 129. Ethicon, Inc. Business Overview Table 130. Ethicon, Inc. Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Ethicon, Inc. Obesity Diagnosis and Treatment Product Portfolio Table 132. Ethicon, Inc. Recent Development Table 133. AstraZeneca Company Information Table 134. AstraZeneca Business Overview Table 135. AstraZeneca Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. AstraZeneca Obesity Diagnosis and Treatment Product Portfolio Table 137. AstraZeneca Recent Development Table 138. Takeda Pharmaceutical Company Company Information Table 139. Takeda Pharmaceutical Company Business Overview Table 140. Takeda Pharmaceutical Company Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Takeda Pharmaceutical Company Obesity Diagnosis and Treatment Product Portfolio Table 142. Takeda Pharmaceutical Company Recent Development Table 143. Currax Pharmaceuticals Company Information Table 144. Currax Pharmaceuticals Business Overview Table 145. Currax Pharmaceuticals Obesity Diagnosis and Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Currax Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio Table 147. Currax Pharmaceuticals Recent Development Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Obesity Diagnosis and Treatment Product Image Figure 2. Global Obesity Diagnosis and Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Obesity Diagnosis and Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Obesity Diagnosis and Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Medication Image Figure 8. Surgery Image Figure 9. Fitness Image Figure 10. Others Image Figure 11. Global Obesity Diagnosis and Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Obesity Diagnosis and Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Obesity Diagnosis and Treatment Sales Value Share by Type (2021-2032) Figure 14. <18 Years Old Image Figure 15. 18-35 Years Old Image Figure 16. 36-45 Years Old Image Figure 17. 45-55 Years Old Image Figure 18. >55 Years Old Image Figure 19. Global Obesity Diagnosis and Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Obesity Diagnosis and Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Obesity Diagnosis and Treatment Sales Value Share by Application (2021-2032) Figure 22. Global Obesity Diagnosis and Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Obesity Diagnosis and Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Obesity Diagnosis and Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. North America Obesity Diagnosis and Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Obesity Diagnosis and Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Obesity Diagnosis and Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Obesity Diagnosis and Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Obesity Diagnosis and Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Obesity Diagnosis and Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. South America Obesity Diagnosis and Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Obesity Diagnosis and Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Obesity Diagnosis and Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Medication
  • Surgery
  • Fitness
  • Others
Applications
  • <18 Years Old
  • 18-35 Years Old
  • 36-45 Years Old
  • 45-55 Years Old
  • >55 Years Old
Companies covered
  • Obesity diagnosis and treatment
  • GlaxoSmithKline
  • Arena Pharmaceuticals
  • Pfizer
  • Allergan
  • Obalon Therapeutics
  • Nalpropion Pharmaceuticals
  • Novo Nordisk
  • Beijing Noble Laser Technology
  • Eisai
  • Orexigen Therapeutics
  • ReShape Lifesciences
  • Roche
  • Allurion Technologies
  • Medtronic
  • VIVUS
  • ApolloEndosurgery
  • Ethicon, Inc.
  • AstraZeneca
  • Takeda Pharmaceutical Company
  • Currax Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Obesity Diagnosis and Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Obesity Diagnosis and Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Obesity Diagnosis and Treatment Market Dynamics
  1. 2.1 Obesity Diagnosis and Treatment Industry Trends
  2. 2.2 Obesity Diagnosis and Treatment Industry Drivers
  3. 2.3 Obesity Diagnosis and Treatment Industry Opportunities and Challenges
  4. 2.4 Obesity Diagnosis and Treatment Industry Restraints
3 Obesity Diagnosis and Treatment Market by Company
  1. 3.1 Global Obesity Diagnosis and Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Obesity Diagnosis and Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Obesity Diagnosis and Treatment Company Ranking (2024-2026)
  4. 3.4 Global Obesity Diagnosis and Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Obesity Diagnosis and Treatment Company Product Type and Application
  6. 3.6 Global Obesity Diagnosis and Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Obesity Diagnosis and Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Obesity Diagnosis and Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Obesity Diagnosis and Treatment Market by Type
  1. 4.1 Obesity Diagnosis and Treatment Type Introduction
  2. 4.1.1 Medication
  3. 4.1.2 Surgery
  4. 4.1.3 Fitness
  5. 4.1.4 Others
  6. 4.2 Global Obesity Diagnosis and Treatment Sales Value by Type
  7. 4.2.1 Global Obesity Diagnosis and Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Obesity Diagnosis and Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Obesity Diagnosis and Treatment Sales Value Share by Type (2021-2032)
5 Obesity Diagnosis and Treatment Market by Application
  1. 5.1 Obesity Diagnosis and Treatment Application Introduction
  2. 5.1.1 <18 Years Old
  3. 5.1.2 18-35 Years Old
  4. 5.1.3 36-45 Years Old
  5. 5.1.4 45-55 Years Old
  6. 5.1.5 >55 Years Old
  7. 5.2 Global Obesity Diagnosis and Treatment Sales Value by Application
  8. 5.2.1 Global Obesity Diagnosis and Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Obesity Diagnosis and Treatment Sales Value by Application (2021-2032)
  10. 5.2.3 Global Obesity Diagnosis and Treatment Sales Value Share by Application (2021-2032)
6 Obesity Diagnosis and Treatment Regional Value Analysis
  1. 6.1 Global Obesity Diagnosis and Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Obesity Diagnosis and Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Obesity Diagnosis and Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Obesity Diagnosis and Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Obesity Diagnosis and Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Obesity Diagnosis and Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Obesity Diagnosis and Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Obesity Diagnosis and Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Obesity Diagnosis and Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Obesity Diagnosis and Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Obesity Diagnosis and Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Obesity Diagnosis and Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Obesity Diagnosis and Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Obesity Diagnosis and Treatment Sales Value Share by Country, 2025 VS 2032
7 Obesity Diagnosis and Treatment Country-level Value Analysis
  1. 7.1 Global Obesity Diagnosis and Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Obesity Diagnosis and Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Obesity Diagnosis and Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Obesity Diagnosis and Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Obesity Diagnosis and Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Obesity Diagnosis and Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Obesity Diagnosis and Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Obesity diagnosis and treatment
  2. 8.1.1 Obesity diagnosis and treatment Company Information
  3. 8.1.2 Obesity diagnosis and treatment Business Overview
  4. 8.1.3 Obesity diagnosis and treatment Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Obesity diagnosis and treatment Obesity Diagnosis and Treatment Product Portfolio
  6. 8.1.5 Obesity diagnosis and treatment Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Obesity Diagnosis and Treatment Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Arena Pharmaceuticals
  14. 8.3.1 Arena Pharmaceuticals Company Information
  15. 8.3.2 Arena Pharmaceuticals Business Overview
  16. 8.3.3 Arena Pharmaceuticals Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Arena Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
  18. 8.3.5 Arena Pharmaceuticals Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Obesity Diagnosis and Treatment Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Allergan
  26. 8.5.1 Allergan Company Information
  27. 8.5.2 Allergan Business Overview
  28. 8.5.3 Allergan Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Allergan Obesity Diagnosis and Treatment Product Portfolio
  30. 8.5.5 Allergan Recent Developments
  31. 8.6 Obalon Therapeutics
  32. 8.6.1 Obalon Therapeutics Company Information
  33. 8.6.2 Obalon Therapeutics Business Overview
  34. 8.6.3 Obalon Therapeutics Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Obalon Therapeutics Obesity Diagnosis and Treatment Product Portfolio
  36. 8.6.5 Obalon Therapeutics Recent Developments
  37. 8.7 Nalpropion Pharmaceuticals
  38. 8.7.1 Nalpropion Pharmaceuticals Company Information
  39. 8.7.2 Nalpropion Pharmaceuticals Business Overview
  40. 8.7.3 Nalpropion Pharmaceuticals Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nalpropion Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
  42. 8.7.5 Nalpropion Pharmaceuticals Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Obesity Diagnosis and Treatment Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Beijing Noble Laser Technology
  50. 8.9.1 Beijing Noble Laser Technology Company Information
  51. 8.9.2 Beijing Noble Laser Technology Business Overview
  52. 8.9.3 Beijing Noble Laser Technology Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Noble Laser Technology Obesity Diagnosis and Treatment Product Portfolio
  54. 8.9.5 Beijing Noble Laser Technology Recent Developments
  55. 8.10 Eisai
  56. 8.10.1 Eisai Company Information
  57. 8.10.2 Eisai Business Overview
  58. 8.10.3 Eisai Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Obesity Diagnosis and Treatment Product Portfolio
  60. 8.10.5 Eisai Recent Developments
  61. 8.11 Orexigen Therapeutics
  62. 8.11.1 Orexigen Therapeutics Company Information
  63. 8.11.2 Orexigen Therapeutics Business Overview
  64. 8.11.3 Orexigen Therapeutics Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Orexigen Therapeutics Obesity Diagnosis and Treatment Product Portfolio
  66. 8.11.5 Orexigen Therapeutics Recent Developments
  67. 8.12 ReShape Lifesciences
  68. 8.12.1 ReShape Lifesciences Company Information
  69. 8.12.2 ReShape Lifesciences Business Overview
  70. 8.12.3 ReShape Lifesciences Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ReShape Lifesciences Obesity Diagnosis and Treatment Product Portfolio
  72. 8.12.5 ReShape Lifesciences Recent Developments
  73. 8.13 Roche
  74. 8.13.1 Roche Company Information
  75. 8.13.2 Roche Business Overview
  76. 8.13.3 Roche Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Roche Obesity Diagnosis and Treatment Product Portfolio
  78. 8.13.5 Roche Recent Developments
  79. 8.14 Allurion Technologies
  80. 8.14.1 Allurion Technologies Company Information
  81. 8.14.2 Allurion Technologies Business Overview
  82. 8.14.3 Allurion Technologies Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Allurion Technologies Obesity Diagnosis and Treatment Product Portfolio
  84. 8.14.5 Allurion Technologies Recent Developments
  85. 8.15 Medtronic
  86. 8.15.1 Medtronic Company Information
  87. 8.15.2 Medtronic Business Overview
  88. 8.15.3 Medtronic Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Medtronic Obesity Diagnosis and Treatment Product Portfolio
  90. 8.15.5 Medtronic Recent Developments
  91. 8.16 VIVUS
  92. 8.16.1 VIVUS Company Information
  93. 8.16.2 VIVUS Business Overview
  94. 8.16.3 VIVUS Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 VIVUS Obesity Diagnosis and Treatment Product Portfolio
  96. 8.16.5 VIVUS Recent Developments
  97. 8.17 ApolloEndosurgery
  98. 8.17.1 ApolloEndosurgery Company Information
  99. 8.17.2 ApolloEndosurgery Business Overview
  100. 8.17.3 ApolloEndosurgery Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ApolloEndosurgery Obesity Diagnosis and Treatment Product Portfolio
  102. 8.17.5 ApolloEndosurgery Recent Developments
  103. 8.18 Ethicon, Inc.
  104. 8.18.1 Ethicon, Inc. Company Information
  105. 8.18.2 Ethicon, Inc. Business Overview
  106. 8.18.3 Ethicon, Inc. Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Ethicon, Inc. Obesity Diagnosis and Treatment Product Portfolio
  108. 8.18.5 Ethicon, Inc. Recent Developments
  109. 8.19 AstraZeneca
  110. 8.19.1 AstraZeneca Company Information
  111. 8.19.2 AstraZeneca Business Overview
  112. 8.19.3 AstraZeneca Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  113. 8.19.4 AstraZeneca Obesity Diagnosis and Treatment Product Portfolio
  114. 8.19.5 AstraZeneca Recent Developments
  115. 8.20 Takeda Pharmaceutical Company
  116. 8.20.1 Takeda Pharmaceutical Company Company Information
  117. 8.20.2 Takeda Pharmaceutical Company Business Overview
  118. 8.20.3 Takeda Pharmaceutical Company Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Takeda Pharmaceutical Company Obesity Diagnosis and Treatment Product Portfolio
  120. 8.20.5 Takeda Pharmaceutical Company Recent Developments
  121. 8.21 Currax Pharmaceuticals
  122. 8.21.1 Currax Pharmaceuticals Company Information
  123. 8.21.2 Currax Pharmaceuticals Business Overview
  124. 8.21.3 Currax Pharmaceuticals Obesity Diagnosis and Treatment Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Currax Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
  126. 8.21.5 Currax Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst